Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- AZ Japan Facing Civil Lawsuit over Demotions, Pay Cuts
July 21, 2017
- Whistleblower Bayer Rep Raps “No Instruction” Finding in Xarelto Scandal Probe
July 21, 2017
- Takecab Most Promoted Drug for Hospital Doctors for 7th Month: Anterio
July 21, 2017
- NanoCarrier’s Micellar Nanoparticle Drug Gets FDA Orphan Status
July 20, 2017
- Kowa President Has High Hopes for Livalo Successor Parmodia
July 20, 2017
- Zymeworks Gains US$1 Million from Daiichi Sankyo in Bispecific Antibody Milestone
July 20, 2017
- Hisamitsu Begins New Japan PIII for NSAIDs Patch after Unfavorable PII/III
July 20, 2017
- Takeda-Teva JV to Discontinue Sale of 53 Generic APIs
July 19, 2017
- JCR, Teijin to Codevelop Regenerative Medicine Product, Plan to Begin Clinical Studies in 2018
July 19, 2017
- Sunovion to Divest Asthma and Allergy Products to Focus on COPD
July 18, 2017
- Bayer Yakuhin to Ban Any Type of Medical Affairs Work by Sales Organization
July 18, 2017
- Probe Finds No HQ Instruction for Improper Patient Info Acquisition in Xarelto Surveys, Bayer Execs Take 3-Month Pay Cuts
July 18, 2017
- Nichi-Iko’s Remicade Biosimilar Filed in 2 Routes, Ayumi to Also Market It under Different Trade Name
July 14, 2017
- Ambicion, RIKEN Pair Up for Joint Research to Develop Novel Antiallergics
July 14, 2017
- Debiopharm’s Appeal on Elplat Patent Suit Rejected: Nippon Chemiphar/Nagase
July 13, 2017
- Daiichi Sankyo Links Up with Max Planck Innovation, LDC on Cancer Research
July 13, 2017
- Vemlidy Counterfeit with Japanese Label Found in China
July 13, 2017
- Biogen, Univ. of Tokyo Establish Research Program on “Pharmacotherapeutics for Neuropsychiatric Disorders”
July 13, 2017
- Astellas Pursuing Corrective Measures after ABPI Suspension Extension: CEO
July 12, 2017
- Astellas Eager to Take in External Resources; Key Xtandi Data Out Later This Year
July 12, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…